(Our) Investors

Research Grants


Best Research Project

Fundació la Marató de TV3 (2015)


Proyectos de investigación en salud (FIS)

Instituto de Salud Carlos III (2018)


Research award Catalan Society of Cardiology


Public & Private Grants


EIC Accelerator 2023

Awarded grant 2.3M€


2023 Women TechEU program. Horizon EIE SCALEUP

European Innovation Council and SMEs Executive Agency (EISMEA)

Awards & Recognitions


Ship2B Impact Business recognition Ship2B Foundation (2022)

With the support of the European Society of Cardiology and the Col·legi oficial de Metges de Barcelona (COMB)


Current state of development

NIMBLE Diagnostics’ technology is currently positioned at TRL 5-6, with a prototype ready for clinical validation. To date we have obtained excellent results in the in vitro determination of electromagnetic signature of stents and the absorption rate analysis of bioabsorbable stents; The ex vivo validation of implanted stents in coronary arteries (analysing fractures, diametrical stent collapse (recoil), and neointimal atherosclerotic transformation inside a stent (in-stent restenosis); And the in vivo validation in murine and swine animal models, where we compared our diagnostic capabilities to histological analysis in several relevant clinical scenarios.

These advances have allowed us to refine the technology and our algorithms, to process the microwave resonance data and transform it into relevant clinical outcomes without requiring any training or interpretation by the clinician. All R&D activities have resulted in a system that accurately measures and quantifies stent malfunction in vivo  non-invasively .
We expect to start the first clinical testing in patients early 2024, which will allow NIMBLE Diagnostics to further advance towards CE and FDA approval and commercialization of our technology in the near future.


Don't miss anything!

Get to know our lastest news: